US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

58.76

+1.392.43%

Post-market: 58.800.0430+0.07%19:30 EDT

Volume:17.38K

Turnover:1.02M

Market Cap:284.38M

PE:19.22

High:59.14

Open:57.66

Low:57.66

Close:57.37

52wk High:64.10

52wk Low:44.47

Shares:4.84M

Float Shares:4.84M

Volume Ratio:0.51

T/O Rate:0.36%

Dividend:1.53

Dividend Rate:2.60%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer

MT Newswires Live

Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

THOMSON REUTERS

Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities

Long-Term Bribery Involving 30+ Pharmaceutical Firms Prompts Hospital Response

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)

Hospital Staff in Hebei Province Found Guilty of Accepting Bribes 46 Times Over 11 Years, Totaling 184 Million Yuan

MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds

Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Tellgen's Subsidiary Device Registration Application Accepted by Regulator

LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live

Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/PTH/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":58.757,"timestamp":1791576000000,"preClose":57.3658,"halted":0,"volume":17383,"hourTrading":{"tag":"盘后","latestPrice":58.8,"preClose":58.757,"latestTime":"19:30 EDT","volume":6,"amount":352.2346,"timestamp":1791588604239,"change":0.043,"changeRate":0.000732,"amplitude":0},"delay":0,"changeRate":0.024251383228334613,"floatShares":4840000,"shares":4840000,"eps":3.057033,"marketStatus":"Market Closed","change":1.3912,"latestTime":"10-09 16:00:00 EDT","open":57.66,"high":59.1447,"low":57.66,"amount":1021175.720865,"amplitude":0.025881,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":57.3658,"sharesOutstanding":2480000,"nav":57.33757,"aum":287288216.63,"dividendRate":0.02597,"bidAskSpread":0.001697,"preHourTrading":{"tag":"盘前","latestPrice":57.37,"preClose":57.3658,"latestTime":"07:00 EDT","volume":1,"amount":57.37,"timestamp":1791543606921,"change":0.0042,"changeRate":0.000073,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":58.8,"preClose":58.757,"latestTime":"19:30 EDT","volume":6,"amount":352.2346,"timestamp":1791588604239,"change":0.043,"changeRate":0.000732,"amplitude":0},"volumeRatio":0.5106189207267566,"impliedVol":0.2074,"impliedVolPercentile":0.9442},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5106189207267566,"shares":4840000,"dividePrice":1.5259,"high":59.1447,"amplitude":0.025881,"preClose":57.3658,"low":57.66,"week52Low":44.47,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":58.757,"eps":3.057033,"divideRate":0.02597,"volume":17383,"delay":0,"ttmEps":3.057033,"open":57.66,"prevYearClose":49.701,"prevWeekClose":60.2082,"prevMonthClose":60.76,"prevQuarterClose":60.76,"fiveDayClose":60.2082,"twentyDayClose":60.7692,"sixtyDayClose":58.2191},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667695932","title":"Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695932","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695932?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:35","pubTimestamp":1789418122,"startTime":"0","endTime":"0","summary":"Revolution Medicines  said Monday that the US Food and Drug Administration has given breakthrough therapy designation to Rasonque plus chemotherapy to treat pancreatic cancer.The company said Rasonque was recently approved by the US FDA to treat adults with metastatic pancreatic cancer who have received at least one systemic therapy or who are not candidates for multiagent systemic therapy.Revolution said the use of Rasonque plus chemotherapy for treatment-naive metastatic pancreatic adenocarcinoma is still investigational, with safety and efficacy not yet established.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","BK4585","IE00BFTCPJ56.SGD","IDNA","LU0889565916.HKD","BBH","IE00B4R5TH58.HKD","IE0002141913.USD","LABU","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0109394709.USD","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","CANC","PTH","RVMD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667953426","title":"Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2667953426","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667953426?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:15","pubTimestamp":1789416936,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the FDA has granted Breakthrough Therapy Designation to Rasonque, the company’s RAS multi-selective inhi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-granted-breakthrough-therapy-designation-to-rasonque-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-granted-breakthrough-therapy-designation-to-rasonque-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","BBH","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4585","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0109394709.USD","IE00BJT1NW94.SGD","RVMD","IDNA","IE0009354923.USD","LABU","BK4588","PTH","BK4139","IE0009355771.USD","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667087693","title":"Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667087693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667087693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:07","pubTimestamp":1789416443,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EKG","GH","LFSC","BK4551","GNMX","GDOC","LU0320765992.SGD","PTH","BK4535","GNOM","BK4196","BK4588","LU0889565916.HKD","FFOX","LU0109394709.USD","HELX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667769375","title":"Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667769375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667769375?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA3JTDPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0889565916.HKD","RVMD","IDNA","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","PTH","BK4139","CANC","IE0009354923.USD","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466962","title":"Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466962?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:11","pubTimestamp":1789391469,"startTime":"0","endTime":"0","summary":"Bellevue flags US healthcare innovation as driving fresh investment opportunitiesBellevue Group AG flagged patient-outcome innovation as a key driver of healthcare investment opportunities from recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL8lm3Sh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1150488135.SGD","BK4588","LU0068578508.USD","BK4139","LQDA","LU1059921491.USD","IHI","LU0289961442.SGD","LU0985320562.USD","ROIV","LU1894683348.USD","LU0985489474.SGD","BK4585","LU0289739343.SGD","LU1894683264.USD","LU0006061336.USD","LU0130103400.USD","LU1201861165.SGD","BDX","LU1571399168.USD","LU0878866978.SGD","LU1854103824.USD","LU1150488218.USD","PTH","LU0477156797.USD","LU1489326972.SGD","LU0433182093.SGD","LU0130518102.USD","BK4007","LU0511384066.AUD","LU0072461881.USD","IE00BFXG1179.USD","LU0648000940.SGD","LU0162691827.USD","LU1854104046.USD","BK4504","LU1699723380.USD","BK4082","BK4532","UTHR","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122259450","title":"Long-Term Bribery Involving 30+ Pharmaceutical Firms Prompts Hospital Response","url":"https://stock-news.laohu8.com/highlight/detail?id=1122259450","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122259450?lang=en_us&edition=fundamental","pubTime":"2026-09-14 12:21","pubTimestamp":1789359679,"startTime":"0","endTime":"0","summary":"On September 13, China's National Healthcare Security Administration released a report detailing commercial bribery cases in medical institutions' pharmaceutical procurement. The report revealed that...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNG","MDEV","RSPH","09996","LGHT","BK1100","BK1583","IEIH","HART","PTH","LNGR","BK1574","GDOC","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668081","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668081?lang=en_us&edition=fundamental","pubTime":"2026-09-14 01:20","pubTimestamp":1789320035,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Cooper Co (COO) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","IDNA","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0889565916.HKD","PTH","CANC","GB00BDT5M118.USD","BK4137","LU0029874061.USD","LU0128526141.USD","BK4588","BK4581","LU0320765992.SGD","HCSG","BK4198","XLV","IE00BJJMRZ35.SGD","XBI","LU1992135472.HKD","BK4139","LU0109394709.USD","LU1992135399.USD","LU2211815571.USD","LU2272731782.SGD","LABU","BBH","IE00BFTCPJ56.SGD","IE0009354923.USD","LU2272731600.USD","BK4585","COO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173526187","title":"Hospital Staff in Hebei Province Found Guilty of Accepting Bribes 46 Times Over 11 Years, Totaling 184 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1173526187","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173526187?lang=en_us&edition=fundamental","pubTime":"2026-09-13 09:40","pubTimestamp":1789263647,"startTime":"0","endTime":"0","summary":"China's medical insurance regulator, which set up a credit evaluation system for pharmaceutical pricing and procurement in August 2020, has uncovered a significant case of commercial bribery in the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDEV","LNGR","BK1574","HART","GDOC","BK1100","RSPH","09939","IEIH","BK1583","AGNG","MEDX","09996","PTH","BK1515","LGHT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188732548","title":"MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=1188732548","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188732548?lang=en_us&edition=fundamental","pubTime":"2026-09-11 15:40","pubTimestamp":1789112453,"startTime":"0","endTime":"0","summary":"MEDCAPTAIN has officially launched its global offering on the Hong Kong stock exchange. Originating from a small infusion equipment manufacturer, the company has leveraged capital support and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPH","LNGR","LGHT","CALF","BK1100","MEDX","02041","XMMO","MDEV","HART","BK4588","09996","BK1574","KCE","PTH","GDOC","BK1583","159883","IEIH","MYLD","BK4585","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512383","title":"Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512383","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512383?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:01","pubTimestamp":1789088474,"startTime":"0","endTime":"0","summary":"Roivant Sciences director Meghan FitzGerald disposes of USD 798,000 in common sharesRoivant director Meghan FitzGerald exercised stock options for 20,000 common shares at USD 8.8 on Sept. 8.She sold 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL33g4Z7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666516010","title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666516010","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666516010?lang=en_us&edition=fundamental","pubTime":"2026-09-11 05:53","pubTimestamp":1789077203,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Lorence H. Kim disposes of 17,090 common shares worth USD 3.57 millionDirector Lorence H. Kim disclosed sales of 17,090 Revolution Medicines common shares on Sep. 8, 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL1wDHJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00BFTCPJ56.SGD","BK4139","LU0889565916.HKD","IE0009354923.USD","IE00B4R5TH58.HKD","RVMD","IE0002141913.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0320765992.SGD","IDNA","IE0009355771.USD","PTH","BBH","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518829","title":"Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518829","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666518829?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:40","pubTimestamp":1789065600,"startTime":"0","endTime":"0","summary":"Revolution Medicines barely had time to celebrate the landmark approval of its pancreatic cancer pill before Wall Street demanded to know what's next.Late last month, regulators approved daraxonrasib ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1718418525.SGD","LU2133065610.SGD","CANC","IE0009355771.USD","LU0096364046.USD","LU1868836757.USD","PTH","LU1670711040.USD","RVMD","LU1670710588.SGD","LU0882574055.USD","LU0456855351.SGD","LU0114720955.EUR","LU0109394709.USD","LU0985481810.HKD","LU1236620750.USD","IHE","LU1571399168.USD","BBH","FTXH","IE00BFXG1179.USD","LU1430594728.SGD","LU1983299246.USD","LU0868494617.USD","BK4581","IE0002141913.USD","LU0237698245.USD","LU1868836591.USD","LU2360032135.SGD","BK4534","IE00BSNM7G36.USD","LU1585245621.USD","IDNA","IE00BFTCPJ56.SGD","IE0009354923.USD","LU1093756168.USD","IE00BJT1NW94.SGD","LU0432979614.USD","LU1868837300.USD","LU2125154935.USD","LU1032466523.USD","BMY","BK4559","LU0321505439.SGD","LU0321505868.SGD","LU0267386448.USD","LU0306806265.USD","BK4588","LU1236620834.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666359288","title":"Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666359288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666359288?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:29","pubTimestamp":1789054182,"startTime":"0","endTime":"0","summary":"Revolution Medicines  could see strong long-term growth from Rasonque sales, expansion into earlier treatment, and new drugs and combination therapies pending upcoming trial results, Morgan Stanley said in a note Thursday.Morgan Stanley models about $12 billion in peak risk-adjusted sales across the company's drug portfolio by 2036, with potential sales of about $18 billion before adjusting for development risks, according to the note.The analysts see Rasonque as the company's main commercial base, while zoldonrasib, elironrasib and earlier-stage drugs could provide additional  sources of growth and reduce reliance on one treatment, while combination treatments could become an important long-term driver by helping the company reach patients earlier in treatment and expand into more cancer types.The next 12 to 18 months will include the US launch of Rasonque, updates in colorectal cancer, progress from early-stage drugs and several late-stage studies, though weaker drug uptake or disapp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBH","CANC","IE0002141913.USD","IE00BJT1NW94.SGD","PTH","RVMD","IE0009354923.USD","IDNA","LU0889565916.HKD","IE0009355771.USD","LU0109394709.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4139","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666996625","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666996625","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666996625?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047034,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-axsome-therapeutics-axsm-and-ocugen-ocgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-axsome-therapeutics-axsm-and-ocugen-ocgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4581","BK4563","AXSM","BK4588","LU0128526141.USD","PTH","HCSG","BK4007","XLV","LU2324357040.USD","XBI","BK4568","BK4137","BK4585","ZYME","BK4505","BK4139","LABU","OCGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666640045","title":"Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255","url":"https://stock-news.laohu8.com/highlight/detail?id=2666640045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666640045?lang=en_us&edition=fundamental","pubTime":"2026-09-10 18:09","pubTimestamp":1789034986,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nFWN4520GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0320765992.SGD","IE0009355771.USD","CANC","LU0889565916.HKD","RVMD","PTH","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4139","IE0009354923.USD","IE00B2B36J28.USD","BBH","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566940","title":"BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566940","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566940?lang=en_us&edition=fundamental","pubTime":"2026-09-10 16:32","pubTimestamp":1789029138,"startTime":"0","endTime":"0","summary":"BeOne Medicines FY26 H1 net income climbs to US$464.36 million; revenue rises 32.3% to US$3.22 billionBeOne Medicines posted GAAP net income of US$464.36 million, swinging from profit of US$95.59 mill","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL4kr7R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B2B36J28.USD","LU0889565916.HKD","BBH","LU0109394709.USD","CANC","PTH","IDNA","IE0009354923.USD","IE0009355771.USD","IE0002141913.USD","688235","RVMD","LU0320765992.SGD","IE00BJT1NW94.SGD","BK0239","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199145560","title":"Tellgen's Subsidiary Device Registration Application Accepted by Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1199145560","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199145560?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:54","pubTimestamp":1789012483,"startTime":"0","endTime":"0","summary":"Tellgen Corporation (SZSE: 300642) has announced that its controlling subsidiary, Shanghai Maishi Biotechnology Co., Ltd., recently had its medical device registration application accepted for review...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDEV","PTH","BK1574","BK1100","09996","300642","RSPH","159883","IEIH","GDOC","MEDX","BK0042","HART","BK0046","BK1583","LNGR","LGHT","AGNG","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156894230","title":"LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894230","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894230?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:08","pubTimestamp":1788998900,"startTime":"0","endTime":"0","summary":"LIFETECH SCI (01302) has announced that it received an official written notice from the National Medical Products Administration (NMPA) on September 9, 2026, confirming that the LantvalTM aortic...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","01302","BK1583","PTH","MEDX","HART","MDEV","RSPH","LGHT","BK1100","LNGR","BK1574","AGNG","GDOC","09996","159883","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666368655","title":"UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666368655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666368655?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960920,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LFSC","FFOX","BK4588","BK4551","BK4196","EKG","GNOM","LU0889565916.HKD","LU0109394709.USD","GH","BK4585","GNMX","BK4535","HELX","LU0320765992.SGD","GDOC","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666041535","title":"Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2666041535","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666041535?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}